Fig. 9

lncRNA SNHG12 increased expression stability of PD-L1 via HuR to facilitate NSCLC cell growth and immune escape in vivo. A, B Volume and weight of representative xenograft tumors; C positive rates of Ki67 and CD8 were determined via immunohistochemistry; D SNHG12, PD-L1, and USP8 expression was measured via western blotting; D SNHG12, PD-L1, and USP8 levels were determined via RT-qPCR; E ubiquitination level of PD-L1 in xenograft tumors was determined via Western blot analysis; F positive rates of PD-L1 and USP8 were determined via immunochemistry. **P < 0.01. Data are represented as mean ± standard deviation. Pairwise comparisons in B and D were analyzed using t-test, and multi-group comparisons in A, C, and F were analyzed using two-way ANOVA, followed by Tukey’s multiple comparison test